Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics, Inc. develops clinical-stage biotechnology programs for cancer and rare diseases. Company news centers on TARA-002, an investigational cell-based therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, including updates from the ADVANCED-2 trial in BCG-Unresponsive and BCG-Naïve NMIBC patient groups.
Recurring updates also cover IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving long-term parenteral support. Other company announcements include clinical-conference presentations, FDA designation updates, financial results, equity compensation grants under Nasdaq rules, and capital-raising activity tied to Protara's development-stage pipeline.
Protara Therapeutics (Nasdaq: TARA) announced its participation in the TD Cowen 5th Annual Oncology Innovation Summit. The company, focused on developing transformative therapies for cancer and rare diseases, will have its management team engage in a virtual fireside chat on May 28, 2024, at 3:00 pm ET. This event will be available via live webcast through Protara's website and archived temporarily after the presentation.
Protara Therapeutics, Inc. announced positive three-month data from TARA-002 clinical program in NMIBC, aligned with FDA on IV Choline Chloride path forward, and closed $45.0 million private placement. Cash resources expected to fund operations into 2026. Financially, cash, cash equivalents, and investments total $55.2 million, with $7.7 million increase in R&D expenses and $4.1 million decrease in G&A expenses for Q1 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.